EntryPoint Capital LLC Takes $308,000 Position in Ocular Therapeutix, Inc. $OCUL

Key Points

• EntryPoint Capital LLC acquired a new stake in Ocular Therapeutix, purchasing 42,031 shares valued at approximately $308,000 in the first quarter of the year.
• Ocular Therapeutix reported a quarterly revenue of $13.46 million but had a loss per share (EPS) of ($0.39), missing analyst estimates by $0.04.
• Analysts maintain a consensus rating of "Buy" for Ocular Therapeutix, with a target price ranging from $15.00 to $20.00, indicating expectations of growth for the stock.

EntryPoint Capital LLC purchased a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 42,031 shares of the biopharmaceutical company's stock, valued at approximately $308,000.

Other hedge funds have also made changes to their positions in the company. Hsbc Holdings PLC boosted its position in shares of Ocular Therapeutix by 8.1% in the first quarter. Hsbc Holdings PLC now owns 19,573 shares of the biopharmaceutical company's stock worth $141,000 after buying an additional 1,472 shares during the period. Aptus Capital Advisors LLC increased its holdings in Ocular Therapeutix by 1.9% in the first quarter. Aptus Capital Advisors LLC now owns 346,098 shares of the biopharmaceutical company's stock valued at $2,537,000 after purchasing an additional 6,348 shares during the last quarter. Brooklyn Investment Group boosted its position in shares of Ocular Therapeutix by 151.5% during the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 3,155 shares during the period. Algert Global LLC acquired a new position in Ocular Therapeutix during the first quarter valued at approximately $213,000. Finally, Nuveen LLC acquired a new stake in shares of Ocular Therapeutix in the first quarter valued at approximately $3,035,000. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Trading Up 0.2%

Shares of Ocular Therapeutix stock traded up $0.03 during mid-day trading on Wednesday, hitting $12.35. The stock had a trading volume of 460,077 shares, compared to its average volume of 1,784,021. The firm has a market cap of $2.15 billion, a P/E ratio of -9.63 and a beta of 1.49. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $12.91. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The firm has a 50-day moving average of $11.06 and a two-hundred day moving average of $8.75.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The firm had revenue of $13.46 million during the quarter, compared to analysts' expectations of $13.12 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. Ocular Therapeutix's revenue for the quarter was down 17.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.26) earnings per share. Sell-side analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

OCUL has been the topic of a number of analyst reports. Scotiabank reduced their price target on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating on the stock in a research report on Wednesday, August 6th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Finally, Needham & Company LLC boosted their target price on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of "Buy" and a consensus target price of $17.20.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.